Skip to main content
Erschienen in: Journal of Endocrinological Investigation 10/2019

01.10.2019 | Original Article

Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend

verfasst von: P. Malandrino, D. Tumino, M. Russo, S. Marescalco, R. A. Fulco, F. Frasca

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This is a longitudinal study of retrospective data aimed at verifying whether repeated measurements of serum non-stimulated thyroglobulin (Tg) allow the prediction of persistent disease in patients with differentiated thyroid cancer (DTC) and indeterminate response.

Methods

We examined 145 DTC patients with indeterminate response to therapy followed up for a median time of 68 months. Tg measurements and neck ultrasound (US) were performed every 6–12 months. The changes over time of repeated measurements of basal Tg were analyzed through the multilevel linear regression.

Results

Seventy (48.3%) out of 145 patients spontaneously achieved an excellent response, while persistent indeterminate response was observed in 62 (42.7%) patients. The remaining 13 (9.0%) patients had progression: 3/13 with biochemical disease and 10/13 with structural disease. Tg steadily increased in patients with progressive disease (mean percentage change + 27.1% at each follow-up visit), while Tg decreased in patients without any evidence of progression (mean percentage change − 8.8%). This different trend between the two groups was not related to either different values of median TSH at baseline (0.32 vs 0.28 mIU/l, respectively) or to different trend of TSH during follow-up (p = 0.76). Basal Tg values did not increase in three out of ten patients with structural disease that was identified by neck US.

Conclusions

The importance of the study is that, in DTC patients with indeterminate response, rising values of unstimulated Tg, independently from the basal levels, may be useful to identify patients with progressive disease. These results are also useful to avoid unnecessary TSH stimulation.
Literatur
1.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://​doi.​org/​10.​1089/​thy.​2015.​0020 CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12):1341–1349. https://doi.org/10.1089/thy.2010.0178 CrossRefPubMedPubMedCentral Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12):1341–1349. https://​doi.​org/​10.​1089/​thy.​2010.​0178 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Dominguez JM, Nilo F, Contreras T, Carmona R, Droppelmann N, Gonzalez H, Iturrieta V, Tuttle RM (2017) Neck sonography and suppressed thyroglobulin have high sensitivity for identifying recurrent/persistent disease in patients with low-risk thyroid cancer treated with total thyroidectomy and radioactive iodine ablation, making stimulated thyroglobulin unnecessary. J Ultrasound Med 36(11):2299–2307. https://doi.org/10.1002/jum.14260 CrossRefPubMed Dominguez JM, Nilo F, Contreras T, Carmona R, Droppelmann N, Gonzalez H, Iturrieta V, Tuttle RM (2017) Neck sonography and suppressed thyroglobulin have high sensitivity for identifying recurrent/persistent disease in patients with low-risk thyroid cancer treated with total thyroidectomy and radioactive iodine ablation, making stimulated thyroglobulin unnecessary. J Ultrasound Med 36(11):2299–2307. https://​doi.​org/​10.​1002/​jum.​14260 CrossRefPubMed
5.
Zurück zum Zitat Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, Scollo C, Vigneri R, Pellegriti G (2011) Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 96(6):1703–1709. https://doi.org/10.1210/jc.2010-2695 CrossRefPubMed Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, Scollo C, Vigneri R, Pellegriti G (2011) Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 96(6):1703–1709. https://​doi.​org/​10.​1210/​jc.​2010-2695 CrossRefPubMed
6.
Zurück zum Zitat Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC (2012) Undetectable sensitive serum thyroglobulin (< 0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 97(8):2714–2723. https://doi.org/10.1210/jc.2011-3017 CrossRefPubMed Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC (2012) Undetectable sensitive serum thyroglobulin (< 0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 97(8):2714–2723. https://​doi.​org/​10.​1210/​jc.​2011-3017 CrossRefPubMed
8.
Zurück zum Zitat Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 71(1):115–123. https://doi.org/10.1111/j.1365-2265.2008.03424.x CrossRef Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 71(1):115–123. https://​doi.​org/​10.​1111/​j.​1365-2265.​2008.​03424.​x CrossRef
11.
Zurück zum Zitat Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84(11):3877–3885. https://doi.org/10.1210/jcem.84.11.6094 CrossRefPubMed Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84(11):3877–3885. https://​doi.​org/​10.​1210/​jcem.​84.​11.​6094 CrossRefPubMed
12.
Zurück zum Zitat Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C (2016) Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. Endocrine 54(2):467–475. https://doi.org/10.1007/s12020-015-0823-3 CrossRefPubMed Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C (2016) Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. Endocrine 54(2):467–475. https://​doi.​org/​10.​1007/​s12020-015-0823-3 CrossRefPubMed
14.
Zurück zum Zitat Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86(9):4092–4097. https://doi.org/10.1210/jcem.86.9.7831 CrossRefPubMed Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86(9):4092–4097. https://​doi.​org/​10.​1210/​jcem.​86.​9.​7831 CrossRefPubMed
15.
Zurück zum Zitat Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M (2003) Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88(3):1107–1111. https://doi.org/10.1210/jc.2002-021365 CrossRefPubMed Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M (2003) Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88(3):1107–1111. https://​doi.​org/​10.​1210/​jc.​2002-021365 CrossRefPubMed
16.
Zurück zum Zitat Rosario PW, Furtado Mde S, Mourao GF, Calsolari MR (2015) Patients with papillary thyroid carcinoma at intermediate risk of recurrence according to american thyroid association criteria can be reclassified as low risk when the postoperative thyroglobulin is low. Thyroid 25(11):1243–1248. https://doi.org/10.1089/thy.2015.0294 CrossRefPubMed Rosario PW, Furtado Mde S, Mourao GF, Calsolari MR (2015) Patients with papillary thyroid carcinoma at intermediate risk of recurrence according to american thyroid association criteria can be reclassified as low risk when the postoperative thyroglobulin is low. Thyroid 25(11):1243–1248. https://​doi.​org/​10.​1089/​thy.​2015.​0294 CrossRefPubMed
17.
Zurück zum Zitat Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Inoue H, Tomoda C, Yabuta T, Masuoka H (2011) Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21(7):707–716. https://doi.org/10.1089/thy.2010.0355 CrossRefPubMed Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Inoue H, Tomoda C, Yabuta T, Masuoka H (2011) Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21(7):707–716. https://​doi.​org/​10.​1089/​thy.​2010.​0355 CrossRefPubMed
18.
Zurück zum Zitat Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M, Group TW (2011) Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96(5):1352–1359. https://doi.org/10.1210/jc.2010-2708 CrossRefPubMed Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M, Group TW (2011) Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96(5):1352–1359. https://​doi.​org/​10.​1210/​jc.​2010-2708 CrossRefPubMed
19.
Zurück zum Zitat Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga WM (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150(2):105–112CrossRefPubMed Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga WM (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150(2):105–112CrossRefPubMed
24.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214. https://doi.org/10.1089/thy.2009.0110 CrossRefPubMed Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214. https://​doi.​org/​10.​1089/​thy.​2009.​0110 CrossRefPubMed
Metadaten
Titel
Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend
verfasst von
P. Malandrino
D. Tumino
M. Russo
S. Marescalco
R. A. Fulco
F. Frasca
Publikationsdatum
01.10.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 10/2019
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-019-01044-3

Weitere Artikel der Ausgabe 10/2019

Journal of Endocrinological Investigation 10/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.